Why Hikma Pharmaceuticals (LSE:HIK) Is Getting Attention Today

Hikma Pharmaceuticals (LSE:HIK) has just launched Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Solution in the US after FDA Competitive Generic Therapy approval, placing the group in a limited competition ear infection treatment niche.

Recent trading suggests some momentum is building in Hikma Pharmaceuticals, with a 30-day share price return of 9.56% and a year to date share price gain of 13.66%. This is despite the 1-year total shareholder return being slightly down at 1.48% and the 5-year total shareholder return being down 15.01%.

Capitalize on Hikma Pharmaceuticals' niche US launch by scanning hand-picked peers with resilient balance sheets and fundamentals through the list of solid balance sheet and fundamentals (10 results).

After that sharp move, the question is whether Hikma Pharmaceuticals still offers meaningful upside or if the easy gains are already in the rear-view mirror. Ultimately, this comes down to what you are paying for the current fundamentals.

Most Popular Narrative: 14% Undervalued

Hikma Pharmaceuticals last closed at £17.31, while the most followed narrative sets fair value closer to £20.06. This frames the recent rally as only part of the potential move analysts are modelling using a 7.6% discount rate.

The main thing that has to go right is that Hikma Pharmaceuticals continues to execute on its MENA branded growth strategy, complex respiratory pipeline and expanding CMO contracts while maintaining the higher Rx margins reported in H1 2026.

The respiratory and nasal franchise, including the filed intranasal epinephrine program across multiple regions and the advancing generic Ellipta project that reuses Advair know how and equipment, provides a set of high barrier assets that can add new revenue streams and support mix driven gross margin improvement as they reach the market.

See why 52 investors see Hikma Pharmaceuticals as 14% undervalued.

Result: Fair Value of £20.06 (UNDERVALUED)

Still, Hikma Pharmaceuticals depends heavily on high margin MENA branded profits and complex therapies, where tougher tender terms or weaker pricing could quickly undercut this undervaluation story.

Find out about the key risks to this Hikma Pharmaceuticals narrative.

Next Steps

Mixed messages on Hikma Pharmaceuticals so far. If the risk and reward signals feel finely balanced, it is worth moving quickly and weighing both sides with the 4 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Hikma Pharmaceuticals?

If Hikma Pharmaceuticals has your attention, do not stop there. The next strong portfolio move often comes from the ideas you almost skipped.

• Target potential mispricings by scanning a curated pool of quality companies through the 13 high quality undervalued stocks.
• Lock in consistency by focusing on businesses with robust balance sheets and fundamentals using the list of solid balance sheet and fundamentals (10 results).
• Spot promising smaller opportunities early by zeroing in on 14 elite penny stocks with strong financials before wider attention builds around them.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com